China's medical products administrator granted CSPC Pharmaceutical (HKG:1093) marketing approval for its omalizumab for injection for chronic spontaneous urticaria, according to a Tuesday filing with the Hong Kong Exchange.

The drug is an anti-immunoglobulin E recombinant monoclonal antibody for urticaria patients exhibiting symptoms despite antihistamine treatment, the filing said.

The company's shares closed 1% lower on Tuesday.

Price (HKD): $7.04, Change: $-0.080, Percent Change: -1.12%